{"id":72150,"date":"2026-08-10T12:44:02","date_gmt":"2026-08-10T04:44:02","guid":{"rendered":"https:\/\/flcube.com\/?p=72150"},"modified":"2026-08-10T12:44:03","modified_gmt":"2026-08-10T04:44:03","slug":"grand-pharmas-gpn01530-2-rdc-drug-snags-fda-fast-track-for-solid-tumor-diagnosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72150","title":{"rendered":"Grand Pharma&#8217;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Grand Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/0512:HKG\">HKG:\u202f0512<\/a>) announced that <strong>GPN01530-2<\/strong>, a global innovative <strong>radionuclide drug conjugate (RDC)<\/strong> independently developed for the <strong>diagnosis of solid tumors<\/strong>, has been granted <strong>Fast Track Designation (FTD)<\/strong> by the <strong>US Food and Drug Administration (FDA)<\/strong>. The designation covers the candidate&#8217;s development path in <strong>oncologic imaging<\/strong>, positioning Grand Pharma at the forefront of the emerging <strong>theranostics<\/strong> wave.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Grand Pharmaceutical Group Limited (HKG:\u202f0512)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>US Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Fast Track Designation (FTD)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GPN01530-2<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Radionuclide drug conjugate (RDC); small\u2011molecule<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Fibroblast activation protein (FAP)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Diagnosis of solid tumors<\/td><\/tr><tr><td><strong>Prior Regulatory Status<\/strong><\/td><td>FDA clearance for Phase\u202f1\/2 study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Small\u2011molecule <strong>radionuclide drug conjugate (RDC)<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Fibroblast activation protein (FAP)<\/strong>, a key marker of <strong>cancer\u2011associated fibroblasts (CAFs)<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First\u2011in\u2011class FAP\u2011targeted RDC designed for <strong>tumor theranostics<\/strong> \u2014 combining diagnostic imaging with therapeutic potential<\/li>\n\n\n\n<li><strong>Imaging Modality:<\/strong> PET\/CT diagnostic agent<\/li>\n\n\n\n<li><strong>Differentiator:<\/strong> Unlike conventional <strong>fluorine\u201118 fluorodeoxyglucose (\u00b9\u2078F\u2011FDG)<\/strong>, which tracks glucose metabolism non\u2011specifically, GPN01530\u20112 binds <strong>FAP\u2011expressing CAFs<\/strong> in the tumor microenvironment, offering <strong>tumor\u2011specific targeting<\/strong><\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Independently developed by <strong>Grand Pharmaceutical Group<\/strong> with global rights<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-amp-competitive-position\" class=\"wp-block-heading\">Clinical Evidence &amp; Competitive Position<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>GPN01530\u20112<\/th><th>\u00b9\u2078F\u2011FDG (Standard of Care)<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Specificity<\/strong><\/td><td>FAP\u2011expressing CAFs<\/td><td>Glucose metabolism (non\u2011specific)<\/td><td><strong>Tumor\u2011selective binding<\/strong><\/td><\/tr><tr><td><strong>Image Contrast<\/strong><\/td><td><strong>Superior clinical image contrast<\/strong><\/td><td>Standard contrast<\/td><td><strong>Enhanced lesion delineation<\/strong><\/td><\/tr><tr><td><strong>Positive Lesion Detection<\/strong><\/td><td><strong>More accurate detection<\/strong><\/td><td>Baseline accuracy<\/td><td><strong>Reduced false\u2011negative rate<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Broad solid tumor indication<\/td><td>Broad but less specific<\/td><td>Potential to expand diagnostic utility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">In the Phase\u202f1\/2 study cleared by the FDA, GPN01530\u20112 demonstrated <strong>superior clinical image contrast<\/strong> and <strong>more accurate detection of positive lesions<\/strong> compared to \u00b9\u2078F\u2011FDG, the current standard PET\/CT imaging agent. The FAP\u2011targeting mechanism allows the drug to home in on the tumor stroma rather than relying on metabolic uptake, a distinction that could prove critical in tumors with low glycolytic activity or high background glucose signal.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Theranostics Wave:<\/strong> The global <strong>radiopharmaceutical theranostics<\/strong> market is projected to exceed <strong>$15\u202fbillion<\/strong> by 2030, driven by the convergence of precision diagnostics and targeted radiotherapy. GPN01530\u20112&#8217;s diagnostic\u2011first positioning lays the groundwork for a potential companion therapeutic RDC sharing the same FAP target.<\/li>\n\n\n\n<li><strong>Solid Tumor Opportunity:<\/strong> Unlike prostate\u2011specific membrane antigen (PSMA) agents limited to prostate cancer, <strong>FAP is expressed across a wide range of solid tumors<\/strong>, giving GPN01530\u20112 a broad addressable market spanning lung, gastric, pancreatic, and colorectal cancers, among others.<\/li>\n\n\n\n<li><strong>China\u2011US Dual Track:<\/strong> Grand Pharma is pursuing parallel development in China and the US, a strategy that could accelerate global regulatory alignment and attract multinational partnership interest.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> While <strong>Sofie Biosciences \/ iTheranostics<\/strong> and <strong>Clovis Oncology \/ 3B Pharmaceuticals<\/strong> have explored FAP\u2011targeted agents, GPN01530\u20112 is among the most advanced small\u2011molecule FAP\u2011RDC candidates to receive FDA Fast Track status, potentially securing a <strong>first\u2011mover advantage<\/strong> in the FAP\u2011theranostic diagnostic segment.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> The FTD enables more frequent FDA interactions, rolling review eligibility, and priority review voucher potential. Grand Pharma is expected to initiate patient dosing in the Phase\u202f1\/2 solid tumor imaging trial in Q4\u202f2026.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development, regulatory timeline, and commercial potential of GPN01530\u20112. Actual results may differ materially due to risks including clinical trial outcomes, manufacturing scale\u2011up, regulatory requirements, competitive dynamics, and market acceptance. The Fast Track Designation does not guarantee approval. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,683,1184],"class_list":["post-72150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-grand-pharmaceutical","tag-hkg-0512"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Grand Pharma&#039;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate&#039;s development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72150\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma&#039;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis\" \/>\n<meta property=\"og:description\" content=\"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate&#039;s development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72150\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:44:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:44:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma&#8217;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis\",\"datePublished\":\"2026-08-10T04:44:02+00:00\",\"dateModified\":\"2026-08-10T04:44:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150\"},\"wordCount\":599,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1002.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Grand Pharmaceutical\",\"HKG: 0512\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72150#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72150\",\"name\":\"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1002.webp\",\"datePublished\":\"2026-08-10T04:44:02+00:00\",\"dateModified\":\"2026-08-10T04:44:03+00:00\",\"description\":\"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate's development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72150\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72150#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma&#8217;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis - Insight, China&#039;s Pharmaceutical Industry","description":"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate's development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72150","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis","og_description":"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate's development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.","og_url":"https:\/\/flcube.com\/?p=72150","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:44:02+00:00","article_modified_time":"2026-08-10T04:44:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72150#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72150"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma&#8217;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis","datePublished":"2026-08-10T04:44:02+00:00","dateModified":"2026-08-10T04:44:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72150"},"wordCount":599,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","keywords":["ADC \/ XDC","Grand Pharmaceutical","HKG: 0512"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72150#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72150","url":"https:\/\/flcube.com\/?p=72150","name":"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72150#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72150#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","datePublished":"2026-08-10T04:44:02+00:00","dateModified":"2026-08-10T04:44:03+00:00","description":"Grand Pharmaceutical Group Limited (HKG:\u202f0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC) independently developed for the diagnosis of solid tumors, has been granted Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). The designation covers the candidate's development path in oncologic imaging, positioning Grand Pharma at the forefront of the emerging theranostics wave.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72150#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72150"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72150#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","width":1080,"height":608,"caption":"Grand Pharma's GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72150#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma&#8217;s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72150"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72150\/revisions"}],"predecessor-version":[{"id":72154,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72150\/revisions\/72154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72153"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}